Published by Coherent Market Insights
Posted on September 27, 2021
“The Cryptococcosis Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/147
The growing prevalence of cryptococcus disease is escalating the growth of the cryptococcosis treatment market. The Centers for Disease Control and Prevention (CDC) states that around 1 million cryptococcosis cases arise throughout the globe, and it is anticipated that annually, the number of deaths associated with cryptococcosis is around 650,000. Most of the cases are reported among patients with complex HIV disease. Moreover, rising count of people being contaminated by the disease such as AIDS is propelling the growth of the cryptococcosis treatment. India has the third-largest HIV epidemic in the world. In 2017, HIV prevalence among adults (aged 15-49) was an estimated 0.2%. HIV prevalence is higher among men than women, with 0.25% of men and 0.19% of women living with HIV as of 2017.
In January 2018, Lupin Limited, an Indian pharmaceutical company, launched a generic version of Valeant Pharmaceutical International Inc.’s ‘Ancobon Capsules’. These capsules are indicated for infections caused by Cryptococcus
In September 2017, CHAI’s HIV Access Program launched an online HIV New Product Introduction Toolkit and an accompanying HIV New Product Introduction Guide to provide partners and Ministries of Health with the tools and resources needed to introduce and scale up new optimal antiretrovirals (ARV) in-country
In March 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body
North America is expected to dominate the global cryptococcosis treatment market and this can be attributed to the growing FDA approval for the launch of new products. For instance, in February 2019, Amplyx Pharmaceuticals, a U.S.-based pharmaceutical company, received orphan drug designation for APX001 from the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development. This drug will be used for the treatment of cryptococcosis.
Cryptococcosis, also known as “scooting to death,” is an infectious disease with an agent that causes infection by encapsulation of naturally occurring yeast in the lungs, and sometimes in other body tissues (such as the genital area). It is most commonly associated with the inhalation of contaminated soil where the encapsulated yeast cells produce aerosol particles (or “crypts”) that become airborne and are inhaled. The disease has an incubation period of two to six weeks and is most common after someone has had contact with contaminated soil during camping or traveling.
Top Key Players Include In Cryptococcosis Treatment Market: Bristol-Myers Squibb Company, Sigmapharm Laboratories LLC, Janssen Biotech, Inc. (Johnson & Johnson), Novartis AG, Abbott Laboratories, Valeant Pharmaceuticals, Inc., Pfizer, Inc., and Glenmark Pharmaceuticals.
The Cryptococcosis Treatment Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Cryptococcosis Treatment Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/147
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Cryptococcosis Treatment Market Growth Rate, Manufacturers, Market Shares Amalysis by 2027 appeared first on Gatorledger.
“The Cryptococcosis Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/147
The growing prevalence of cryptococcus disease is escalating the growth of the cryptococcosis treatment market. The Centers for Disease Control and Prevention (CDC) states that around 1 million cryptococcosis cases arise throughout the globe, and it is anticipated that annually, the number of deaths associated with cryptococcosis is around 650,000. Most of the cases are reported among patients with complex HIV disease. Moreover, rising count of people being contaminated by the disease such as AIDS is propelling the growth of the cryptococcosis treatment. India has the third-largest HIV epidemic in the world. In 2017, HIV prevalence among adults (aged 15-49) was an estimated 0.2%. HIV prevalence is higher among men than women, with 0.25% of men and 0.19% of women living with HIV as of 2017.
In January 2018, Lupin Limited, an Indian pharmaceutical company, launched a generic version of Valeant Pharmaceutical International Inc.’s ‘Ancobon Capsules’. These capsules are indicated for infections caused by Cryptococcus
In September 2017, CHAI’s HIV Access Program launched an online HIV New Product Introduction Toolkit and an accompanying HIV New Product Introduction Guide to provide partners and Ministries of Health with the tools and resources needed to introduce and scale up new optimal antiretrovirals (ARV) in-country
In March 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body
North America is expected to dominate the global cryptococcosis treatment market and this can be attributed to the growing FDA approval for the launch of new products. For instance, in February 2019, Amplyx Pharmaceuticals, a U.S.-based pharmaceutical company, received orphan drug designation for APX001 from the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development. This drug will be used for the treatment of cryptococcosis.
Cryptococcosis, also known as “scooting to death,” is an infectious disease with an agent that causes infection by encapsulation of naturally occurring yeast in the lungs, and sometimes in other body tissues (such as the genital area). It is most commonly associated with the inhalation of contaminated soil where the encapsulated yeast cells produce aerosol particles (or “crypts”) that become airborne and are inhaled. The disease has an incubation period of two to six weeks and is most common after someone has had contact with contaminated soil during camping or traveling.
Top Key Players Include In Cryptococcosis Treatment Market: Bristol-Myers Squibb Company, Sigmapharm Laboratories LLC, Janssen Biotech, Inc. (Johnson & Johnson), Novartis AG, Abbott Laboratories, Valeant Pharmaceuticals, Inc., Pfizer, Inc., and Glenmark Pharmaceuticals.
The Cryptococcosis Treatment Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Cryptococcosis Treatment Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/147
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Cryptococcosis Treatment Market Growth Rate, Manufacturers, Market Shares Amalysis by 2027 appeared first on Gatorledger.
Explore more articles in the Research Reports category
